Short Interest in Novozymes A/S (OTCMKTS:NVZMY) Drops By 48.1%

Key Points

• Short interest fell 48.1% in August to 1,871 shares, representing effectively 0.0% of Novozymes’ outstanding shares and a 0.0-day short-interest ratio.
• Novozymes shares opened at $71.89, up 0.7%, with a $29.8 billion market capitalization; the stock remains near its 12-month high of $75.27.
• The company reported quarterly EPS of $0.44, missing analysts’ $0.60 estimate, although revenue of $1.30 billion exceeded expectations. Analysts maintain a consensus “Buy” rating.

Novozymes A/S (OTCMKTS:NVZMY - Get Free Report) was the recipient of a significant decrease in short interest during the month of August. As of August 14th, there was short interest totaling 1,871 shares, a decrease of 48.1% from the July 30th total of 3,603 shares. Based on an average trading volume of 38,102 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the company's shares are short sold.

Novozymes A/S Stock Up 0.7%

Shares of OTCMKTS:NVZMY opened at $71.89 on Friday. The company has a market capitalization of $29.80 billion, a PE ratio of 45.50, a P/E/G ratio of 3.16 and a beta of 0.92. The company has a current ratio of 1.67, a quick ratio of 1.03 and a debt-to-equity ratio of 0.27. Novozymes A/S has a twelve month low of $49.90 and a twelve month high of $75.27. The firm has a 50 day simple moving average of $65.12 and a 200-day simple moving average of $61.02.

Novozymes A/S (OTCMKTS:NVZMY - Get Free Report) last issued its earnings results on Thursday, August 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.60 by ($0.16). The company had revenue of $1.30 billion during the quarter, compared to analyst estimates of $1.27 billion. Novozymes A/S had a net margin of 14.70% and a return on equity of 6.60%. On average, equities analysts predict that Novozymes A/S will post 2.47 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have commented on NVZMY shares. Zacks Research raised shares of Novozymes A/S from a "strong sell" rating to a "hold" rating in a research report on Monday, June 8th. Kepler Capital Markets raised Novozymes A/S from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, May 13th. Two investment analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Buy".

Hedge Funds Weigh In On Novozymes A/S

An institutional investor recently raised its position in Novozymes A/S stock. Elefante Mark B lifted its position in shares of Novozymes A/S (OTCMKTS:NVZMY - Free Report) by 73.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,900 shares of the biotechnology company's stock after purchasing an additional 2,500 shares during the period. Elefante Mark B's holdings in Novozymes A/S were worth $371,000 at the end of the most recent reporting period. Institutional investors own 0.03% of the company's stock.

Novozymes A/S Company Profile

Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.

The company's product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source